Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCAX Bicara Therapeutics	$11.91 -0.9%	$10.59	$7.80 ▼ $28.09	$655.85M	N/A	311,966 shs	244,362 shs
BDTX Black Diamond Therapeutics	$2.85 -0.7%	$2.73	$1.20 ▼ $6.37	$163.40M	2.87	891,013 shs	417,149 shs
KURA Kura Oncology	$8.07 +2.7%	$6.39	$5.41 ▼ $21.57	$682.23M	0.41	1.84 million shs	3.06 million shs
SIGA Siga Technologies	$8.21 -0.5%	$7.37	$4.95 ▼ $9.62	$590.75M	0.94	668,906 shs	324,065 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCAX Bicara Therapeutics	-0.92%	+2.41%	+3.66%	+28.34%	+1,190,999,900.00%
BDTX Black Diamond Therapeutics	-0.70%	+5.17%	+2.52%	+27.80%	-55.22%
KURA Kura Oncology	+2.67%	+8.47%	+26.69%	+42.08%	-59.93%
SIGA Siga Technologies	-0.48%	-6.17%	+17.12%	+36.61%	-10.86%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BCAX Bicara Therapeutics	1.8524 of 5 stars	3.5	0.0	0.0	1.8	0.8	0.6
BDTX Black Diamond Therapeutics	3.4093 of 5 stars	3.6	1.0	0.0	4.3	1.7	1.9
KURA Kura Oncology	4.0125 of 5 stars	3.4	3.0	4.7	2.6	0.0	0.6
SIGA Siga Technologies	1.9124 of 5 stars	0.0	2.0	0.0	2.2	0.8	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCAX Bicara Therapeutics	3.00	Buy	$32.25	170.79% Upside
BDTX Black Diamond Therapeutics	3.17	Buy	$12.40	335.09% Upside
KURA Kura Oncology	2.86	Moderate Buy	$24.10	198.64% Upside
SIGA Siga Technologies	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest BDTX, KURA, SIGA, and BCAX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/22/2025	BCAX Bicara Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$41.00 ➝ $40.00
8/18/2025	BCAX Bicara Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$36.00
8/12/2025	BCAX Bicara Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$30.00
8/11/2025	BDTX Black Diamond Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/11/2025	BDTX Black Diamond Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $10.00
8/11/2025	KURA Kura Oncology	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$28.00 ➝ $24.00
7/1/2025	BDTX Black Diamond Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform	$11.00
6/26/2025	KURA Kura Oncology	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
6/20/2025	KURA Kura Oncology	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$36.00
6/4/2025	KURA Kura Oncology	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$28.00

(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCAX Bicara Therapeutics	N/A	N/A	N/A	N/A	$7.98 per share	N/A
BDTX Black Diamond Therapeutics	$70M	2.32	N/A	N/A	$2.33 per share	1.22
KURA Kura Oncology	$53.88M	13.00	N/A	N/A	$3.52 per share	2.29
SIGA Siga Technologies	$138.72M	4.24	$0.83 per share	9.86	$2.92 per share	2.81

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCAX Bicara Therapeutics	-$68M	-$3.17	N/A	N/A	N/A	N/A	-21.67%	-20.89%	11/11/2025 (Estimated)
BDTX Black Diamond Therapeutics	-$69.68M	$0.23	12.39	N/A	N/A	N/A	12.70%	9.58%	11/4/2025 (Estimated)
KURA Kura Oncology	-$173.98M	-$2.26	N/A	N/A	N/A	N/A	-52.32%	-29.59%	11/6/2025 (Estimated)
SIGA Siga Technologies	$59.21M	$1.13	7.27	6.57	N/A	45.73%	40.52%	35.62%	11/6/2025 (Estimated)

Latest BDTX, KURA, SIGA, and BCAX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	BCAX Bicara Therapeutics	-$0.54	-$0.50	+$0.04	-$0.50	N/A	N/A
8/7/2025	Q2 2025	BDTX Black Diamond Therapeutics	-$0.25	-$0.19	+$0.06	-$0.19	N/A	N/A
8/7/2025	Q2 2025	KURA Kura Oncology	$0.15	-$0.75	-$0.90	-$0.75	$64.95 million	$15.29 million
8/5/2025	Q2 2025	SIGA Siga Technologies	N/A	$0.49	N/A	$0.49	N/A	$81.12 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCAX Bicara Therapeutics	N/A	N/A	N/A	N/A	N/A
BDTX Black Diamond Therapeutics	N/A	N/A	N/A	N/A	N/A
KURA Kura Oncology	N/A	N/A	N/A	N/A	N/A
SIGA Siga Technologies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCAX Bicara Therapeutics	N/A	25.80	25.80
BDTX Black Diamond Therapeutics	N/A	8.73	8.73
KURA Kura Oncology	0.02	6.16	6.16
SIGA Siga Technologies	N/A	10.09	8.52

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCAX Bicara Therapeutics	N/A
BDTX Black Diamond Therapeutics	95.47%
KURA Kura Oncology	N/A
SIGA Siga Technologies	55.40%

Insider Ownership

Company	Insider Ownership
BCAX Bicara Therapeutics	15.50%
BDTX Black Diamond Therapeutics	5.97%
KURA Kura Oncology	6.40%
SIGA Siga Technologies	1.95%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCAX Bicara Therapeutics	32	54.56 million	46.11 million	N/A
BDTX Black Diamond Therapeutics	90	56.94 million	53.54 million	Optionable
KURA Kura Oncology	130	86.80 million	81.24 million	Optionable
SIGA Siga Technologies	40	71.61 million	70.21 million	Optionable

BDTX, KURA, SIGA, and BCAX Headlines

Recent News About These Companies

Hotchkis & Wiley Capital Management LLC Increases Stock Position in Siga Technologies Inc. $SIGA

August 26 at 6:18 AM | marketbeat.com

Siga Technologies Sees Unusually Large Options Volume (NASDAQ:SIGA)

August 23, 2025 | marketbeat.com

First Wilshire Securities Management Inc. Has $8.70 Million Stock Position in Siga Technologies Inc. $SIGA

August 21, 2025 | marketbeat.com

SIGA Technologies: Still Bullish, But Worth Trimming Ahead Of BARDA News

August 20, 2025 | seekingalpha.com

Siga Technologies (NASDAQ:SIGA) Trading Down 4.9% - Should You Sell?

August 15, 2025 | marketbeat.com

Wall Street Zen Upgrades Siga Technologies (NASDAQ:SIGA) to Strong-Buy

August 10, 2025 | marketbeat.com

SIGA Technologies Second Quarter 2025 Earnings: EPS: US$0.50 (vs US$0.026 in 2Q 2024)

August 8, 2025 | finance.yahoo.com

Siga Technologies (NASDAQ:SIGA) Trading 13.9% Higher - Here's Why

August 7, 2025 | marketbeat.com

SIGA (SIGA) Q2 Revenue Soars 272%

August 7, 2025 | theglobeandmail.com

Siga Technologies (NASDAQ:SIGA) Issues Earnings Results

August 6, 2025 | marketbeat.com

SIGA Technologies (SIGA) Reports Significant Earnings Decline

August 6, 2025 | finance.yahoo.com

SIGA advances pediatric and PEP programs as product revenues reach $79M, supported by new BARDA funding

August 6, 2025 | msn.com

SIGA Technologies, Inc. (SIGA) Q2 2025 Earnings Call Transcript

August 6, 2025 | seekingalpha.com

SIGA Reports Financial Results for Three and Six Months Ended June 30, 2025

August 5, 2025 | globenewswire.com

SIGA to Host Business Update Call on August 5, 2025 Following Release of Second-Quarter 2025 Results

July 29, 2025 | globenewswire.com

Siga Technologies Inc. (SIGA) Stock Falls Amid Market Uptick: What Investors Need to Know

July 24, 2025 | zacks.com

Siga Technologies Inc. (SIGA) Dips More Than Broader Market: What You Should Know

July 15, 2025 | msn.com

US Market's Undiscovered Gems Featuring Three Promising Small Caps

July 15, 2025 | finance.yahoo.com

Siga Technologies Inc. (SIGA) Laps the Stock Market: Here's Why

July 9, 2025 | zacks.com

SIGA Technologies Inc Dividends - Morningstar

July 8, 2025 | morningstar.comM

Why Siga Technologies Inc. (SIGA) Outpaced the Stock Market Today

June 26, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BDTX, KURA, SIGA, and BCAX Company Descriptions

Bicara Therapeutics NASDAQ:BCAX

$11.91 -0.11 (-0.92%)

Closing price 08/28/2025 04:00 PM Eastern

Extended Trading

$11.91 0.00 (0.00%)

As of 08/28/2025 04:11 PM Eastern

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Black Diamond Therapeutics NASDAQ:BDTX

$2.85 -0.02 (-0.70%)

Closing price 08/28/2025 04:00 PM Eastern

Extended Trading

$2.84 0.00 (-0.18%)

As of 04:58 AM Eastern

Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Kura Oncology NASDAQ:KURA

$8.07 +0.21 (+2.67%)

Closing price 08/28/2025 04:00 PM Eastern

Extended Trading

$8.22 +0.15 (+1.92%)

As of 05:14 AM Eastern

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

Siga Technologies NASDAQ:SIGA

$8.21 -0.04 (-0.48%)

Closing price 08/28/2025 04:00 PM Eastern

Extended Trading

$8.12 -0.10 (-1.16%)

As of 04:09 AM Eastern

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time